Table 1.

Characteristics of included studies with CV events as outcome

Author, Year (Reference)Study Duration, MonthsNumber of Patients (Medication)Mean Duration on HD, Months (SD)Mean Baseline SBP, mmHg (SD)Mean Baseline DBP, mmHg (SD)Mean Baseline LVMI, g/m2 (SD)Number of Patients with CAD (%)Number of Patients with DM (%)
TxCTxCTxCTxCTxCTxCTxC
Takahashi, 2006 (27)19.4a43 (candesartan)37 (none)32.9 (34.1)33.2 (49.3)153 (20)152 (24)82 (13)85 (18)143.3 (67.5)152.4 (90.6)0 (0)0 (0)15 (35)11 (30)
Zannad, 2006 (28)24196 (fosinopril)201 (placebo)52.8 (60.0)45.6 (48.0)146 (19)145 (20)77 (11)77 (11)179 (54)169 (52)32 (16)21 (10)68 (35)56 (28)
Suzuki, 2008 (29)36183b (losartan, candesartan, valsartan)183b (none)44.4 (10.8)44.4 (9.6)154 (20)156 (21)81 (12)82 (13)NRNR7 (4)7 (4)91 (50)99 (54)
  • Tx, treatment group; C, control group; HD, hemodialysis; SBP, systolic BP; DBP, diastolic BP; LVMI, LV mass index; CAD, coronary artery disease; DM, diabetes mellitus; NR, not reported.

  • a Study designed to follow patients for 36 months but was terminated after the second interim analysis because of the beneficial effect of candesartan.

  • b 183 randomized to each group, but only 180 per group were included in analysis.